Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a multi-organ disorder characterized by hyper-IgG4 γ-globulinemia, organ infiltration of IgG4-bearing plasma cells, and tissue sclerosis [
1‐
3]. IgG4-RD has recently been recognized as a distinct clinical entity [
1‐
4] comprising a number of disorders, such as type 1 autoimmune pancreatitis (AIP) [
3,
5‐
7], sclerosing cholangitis [
8], Mikulicz's disease (MD) [
1], Küttner's tumor [
9], Riedel thyroiditis [
10], inflammatory aneurysm [
11], tubulointerstitial nephritis [
12], and retroperitoneal fibrosis [
13,
14]. Because the cause of IgG4-RD is unknown, it remains unclear whether this disease should be classified as autoimmune, allergic, or hematologic.
Hypergammaglobulinemia and the existence of disease-related autoantibodies (for example, those against lactoferrin [
15], carbonic anhydrase II (CAII) [
16], amylase-alpha 2A [
17], pancreatic secretory trypsin inhibitor (PSTI) [
18], and plasminogen-binding protein peptide [
19]) support the hypothesis that autoimmunity may participate in the pathogenesis of IgG4-RD. While the mechanism by which B cells preferentially skew IgG4-class switching is still not determined, recent studies with affected tissue [
20,
21] have suggested that T helper 2 (Th2) phenotypes of CD4+T cells and regulatory T cells play a crucial role in excessive production of IgG4 and tissue fibrosis.
B cell-activating factor of the tumor necrosis factor (TNF) family (BAFF, also known as B-lymphocyte stimulator (BLyS) or TNF and apoptosis leukocyte-expressed ligand-1 (TALL-1)) and its homolog, a proliferation-inducing ligand (APRIL, also known as TNF-related death ligand 1 (TRDL-1) or TNF and apoptosis leukocyte-expressed ligand-2 (TALL-2), are members of the trimeric TNF family, and both play an essential role in the homeostasis of peripheral B cells [
22]. Both cytokines are known to be expressed by a variety of cell types, particularly the myeloid-lineage cells [
22,
23]. BAFF is synthesized as a membrane-bound or secreted protein, while APRIL exists solely in the secreted form [
24]. BAFF binds to three receptors - BAFF receptor (BAFF-R), transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), and B cell maturation antigen (BCMA) - which are expressed by B cells, whereas APRIL binds to TACI and BCMA [
25].
BAFF and APRIL are thought to mediate the regulation of B cell maturation, survival, CD40L-independent antibody production, and isotype switching through BAFF-R and TACI [
22,
23,
26,
27]. Because overexpression of BAFF is known to induce B cell hyperactivation and autoimmunity in mice [
28], BAFF has been considered a promoting factor in the pathogenesis of several autoimmune and allergic diseases. In fact, elevated serum levels of BAFF were observed in patients with rheumatoid arthritis (RA) [
29], systemic lupus erythematosus (SLE) [
30], primary Sjögren's syndrome (pSS) [
31,
32], inflammatory myositis (IM) [
33], systemic sclerosis (SSc) [
34], bronchial asthma [
35], and atopic dermatitis [
36], and serum BAFF levels were associated with their clinical activity. In contrast, overexpression of APRIL has not been associated with autoimmunity in mice but leads to enhanced IgM production, T cell-independent type 2 humoral responses, and T cell proliferation [
37]. On the other hand, a lack of APRIL is associated with an increased percentage of CD44
hiCD62L
low effector memory T cells and impaired class switching to IgA [
38,
39]. Although APRIL has been found to be elevated in patients with autoimmune diseases, including SLE [
40], pSS [
32], and multiple sclerosis [
41], it is still under debate whether APRIL has a role in human autoimmunity, and its circulating levels do not parallel those of BAFF.
The aim of this study was to investigate the contribution of BAFF and APRIL in the pathogenesis of IgG4-RD. We assessed serum levels of BAFF and APRIL by ELISA to analyze their association with clinical manifestations, serological parameters, and treatment.
Discussion
This is the first study to demonstrate both an increase in BAFF and APRIL levels in patients with IgG4-RD as well as the differential effects of GC treatment on BAFF and APRIL in patients with IgG4-RD. Promotion of B cell activation, plasmacyte differentiation, and germinal center formation by BAFF and APRIL [
42], and ectopic germinal center formation in lacrimal and salivary glands from patients with MD [
43] suggest that inappropriate BAFF and APRIL may contribute to progressive plasmacyte infiltration and ectopic germinal center formation in the target organs of patients with IgG4-RD. In addition, it has been demonstrated that BAFF and APRIL enhance class switching to produce IgG4 and IgE in the presence of IL-4 [
44,
45]. Previous studies have shown that production of Th2 cytokines, such as IL-4, IL-5, and IL-13 was augmented in the tissue of patients with AIP [
20]. Therefore, increased expression of both cytokines may contribute to the pathogenesis of IgG4-RD in concert with cognate Th2 cells. In particular, three (cases 3, 4 and 12) out of five patients (cases 3, 4, 10, 11 and 12) with high BAFF levels (> 1.5 ng/mL) had positive test results for autoantibodies (for example, RF or anti-SS-A antibody), which is consistent with previous studies showing that serum BAFF levels were correlated with positive results for serum autoantibodies in patients with RA [
29], SLE [
30], pSS [
31], or IM [
33]. BAFF might also play a role in the breakdown of B cell tolerance in patients with IgG4-RD. Recently, it has been reported that serum levels of BAFF were higher in patients with AIP than in those with pancreatic cancer or chronic pancreatitis [
46]. The same studies also demonstrated that serum BAFF levels were significantly correlated with serum levels of IgG and IgG4 in patients with AIP, which was not observed in our cohort. The relatively small number of patients in our study or the enrollment of different subsets of patients might explain this discrepancy.
Of interest, we found an inverse correlation between serum APRIL and serum IgG4 levels in patients with IgG4-RD. In SLE, a similar inverse correlation between serum APRIL levels and anti-double-stranded DNA antibody titers has been reported [
47], and serum APRIL was inversely associated with disease activity. Thus, APRIL might serve as a protective factor against the progression of IgG4-RD. In our cohort, serum IgG4 levels were significantly correlated with the number of affected organs, clearly indicating that serum IgG4 levels reflect disease severity. Although no significant correlation existed between serum BAFF levels and serum immunoglobulins or the number of affected organs, GC treatment dramatically reduced serum levels of BAFF as well as serum IgG4. In patients with AIP, reduced serum levels of BAFF after 12 weeks of GC treatment have been reported [
46], a result similar to our finding. Thus, serum BAFF levels might reflect the clinical activity of this disease. During long-term (up to 26 weeks) follow-up, we observed that the elevated levels of serum BAFF reoccurred in most cases; however, no patients suffered clinical relapse. Further follow-up study will be needed to clarify the relationship between the reoccurrence of elevated serum BAFF and clinical relapse in IgG4-RD. In contrast to the rapid reduction of BAFF by GC treatment, serum levels of APRIL increased over the course of treatment. Similar changes in serum levels of BAFF and APRIL have been reported in patients with GC-treated SLE [
47]. Furthermore, no significant correlation was observed between serum BAFF levels and serum APRIL during GC treatment in our patients (data not shown). Thus, universal but distinct mechanisms might exist to control the expression of BAFF and APRIL during GC treatment.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KK and DK were responsible for the study design, acquisition, analysis and interpretation of data, and manuscript preparation. YH, KK, NY, HY, KO, TF, and TM participated in enrollment of patients and assisted in interpretation of data. All authors have read and approved the manuscript for publication.